;PMID: 10780971
;source_file_847.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..40] = [t:0..40]
;1)sentence:[e:46..191] = [t:46..191]
;2)section:[e:195..300] = [t:195..300]
;3)section:[e:304..429] = [t:304..429]
;4)sentence:[e:433..531] = [t:433..531]
;5)sentence:[e:532..730] = [t:532..730]
;6)sentence:[e:732..934] = [t:732..934]
;7)sentence:[e:935..1028] = [t:935..1028]
;8)sentence:[e:1029..1183] = [t:1029..1183]
;9)sentence:[e:1184..1340] = [t:1184..1340]
;10)sentence:[e:1341..1429] = [t:1341..1429]
;11)sentence:[e:1430..1501] = [t:1430..1501]
;12)sentence:[e:1502..1697] = [t:1502..1697]
;13)sentence:[e:1698..1815] = [t:1698..1815]
;14)sentence:[e:1816..2186] = [t:1816..2186]
;15)sentence:[e:2187..2375] = [t:2187..2375]
;16)section:[e:2379..2424] = [t:2379..2424]

;section 0 Span:0..40
;Br J Pharmacol. 2000 Apr;129(8):1655-67.
(SEC
  (FRAG (NNP:[0..2] Br) (NNP:[3..4] J) (NNP:[5..14] Pharmacol) (.:[14..15] .)
        (CD:[16..20] 2000) (::[21..29] Apr;129-LRB-) (CD:[29..30] 8)
        (-RRB-:[30..31] -RRB-) (CD:[31..36] :1655) (::[36..37] -)
        (CD:[37..39] 67) (.:[39..40] .)))

;sentence 1 Span:46..191
;Identification of the cytochrome P450 enzymes involved in the metabolism of 
;cisapride: in vitro studies of potential co-medication interactions.
;[68..91]:cyp450:"cytochrome P450 enzymes"
;[123..132]:substance:"cisapride"
;[167..177]:substance:"medication"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[46..60] Identification))
      (PP (IN:[61..63] of)
        (NP
          (NP (DT:[64..67] the)
             (NN:[68..78] cytochrome) (NN:[79..83] P450) (NNS:[84..91] enzymes))
          (VP (JJ:[92..100] involved)
            (NP (-NONE-:[100..100] *))
            (PP-CLR (IN:[101..103] in)
              (NP
                (NP (DT:[104..107] the) (NN:[108..118] metabolism))
                (NP (IN:[119..121] of)
                  (NP (NN:[123..132] cisapride)))))))))
    (::[132..133] :)
    (NP
      (NP
        (ADJP (FW:[134..136] in) (FW:[137..142] vitro))
        (NNS:[143..150] studies))
      (PP (IN:[151..153] of)
        (NP (JJ:[154..163] potential)
          (NML (AFX:[164..166] co) (HYPH:[166..167] -)
               (NN:[167..177] medication))
          (NNS:[178..190] interactions))))
    (.:[190..191] .)))

;section 2 Span:195..300
;Bohets H, Lavrijsen K, Hendrickx J, van Houdt J, van Genechten V, Verboven P,
; Meuldermans W, Heykants J.
(SEC
  (FRAG (NNP:[195..201] Bohets) (NNP:[202..203] H) (,:[203..204] ,)
        (NNP:[205..214] Lavrijsen) (NNP:[215..216] K) (,:[216..217] ,)
        (NNP:[218..227] Hendrickx) (NNP:[228..230] J,) (NNP:[231..234] van)
        (NNP:[235..240] Houdt) (NNP:[241..243] J,) (NNP:[244..247] van)
        (NNP:[248..257] Genechten) (NNP:[258..259] V) (,:[259..260] ,)
        (NNP:[261..269] Verboven) (NNP:[270..271] P) (,:[271..272] ,)
        (NNP:[274..285] Meuldermans) (NNP:[286..287] W) (,:[287..288] ,)
        (NNP:[289..297] Heykants) (NNP:[298..300] J.)))

;section 3 Span:304..429
;Janssen Research Foundation, Department of Pharmacokinetics, Turnhoutseweg
;30,  B-2340 Beerse, Belgium. hbohets@janbe.jnj.com
(SEC
  (FRAG (NNP:[304..311] Janssen) (NNP:[312..320] Research)
        (NNP:[321..331] Foundation) (,:[331..332] ,) (NNP:[333..343] Department)
        (IN:[344..346] of) (NNP:[347..363] Pharmacokinetics) (,:[363..364] ,)
        (NNP:[365..378] Turnhoutseweg) (CD:[379..381] 30) (,:[381..382] ,)
        (NNP:[384..385] B) (::[385..386] -) (CD:[386..390] 2340)
        (NNP:[391..397] Beerse) (,:[397..398] ,) (NNP:[399..406] Belgium)
        (.:[406..407] .) (``:[408..421] hbohets@janbe) (NN:[421..429] .jnj.com)))

;sentence 4 Span:433..531
;Cisapride is a prokinetic drug that is widely used to facilitate 
;gastrointestinal tract motility.
;[433..442]:substance:"Cisapride"
;[459..463]:substance:"drug"
(SENT
  (S
    (NP-SBJ (NN:[433..442] Cisapride))
    (VP (VBZ:[443..445] is)
      (NP-PRD
        (NP (DT:[446..447] a) (JJ:[448..458] prokinetic) (NN:[459..463] drug))
        (SBAR
          (WHNP-1 (WDT:[464..468] that))
          (S
            (NP-SBJ-1 (-NONE-:[468..468] *T*))
            (VP (VBZ:[469..471] is)
              (VP
                (ADVP (RB:[472..478] widely))
                (VBN:[479..483] used)
                (NP-1 (-NONE-:[483..483] *))
                (S-PRP
                  (NP-SBJ (-NONE-:[483..483] *))
                  (VP (TO:[484..486] to)
                    (VP (VB:[487..497] facilitate)
                      (NP
                        (NML (JJ:[499..515] gastrointestinal)
                             (NN:[516..521] tract))
                        (NN:[522..530] motility)))))))))))
    (.:[530..531] .)))

;sentence 5 Span:532..730
;Structurally, cisapride is a substituted  piperidinyl benzamide that
;interacts with 5-hydroxytryptamine-4 receptors and  which is largely without
;central depressant or antidopaminergic side-effects.
;[546..555]:substance:"cisapride"
;[574..595]:substance:"piperidinyl benzamide"
;[616..647]:substance:"5-hydroxytryptamine-4 receptors"
(SENT
  (S
    (ADVP (RB:[532..544] Structurally))
    (,:[544..545] ,)
    (NP-SBJ (NN:[546..555] cisapride))
    (VP (VBZ:[556..558] is)
      (NP-PRD
        (NP (DT:[559..560] a) (JJ:[561..572] substituted)
           (NN:[574..585] piperidinyl) (NN:[586..595] benzamide))
        (SBAR
          (SBAR
            (WHNP-3 (WDT:[596..600] that))
            (S
              (NP-SBJ-3 (-NONE-:[600..600] *T*))
              (VP (VBZ:[601..610] interacts)
                (PP-CLR (IN:[611..615] with)
                  (NP (NN:[616..637] 5-hydroxytryptamine-4)
                      (NNS:[638..647] receptors))))))
          (CC:[648..651] and)
          (SBAR
            (WHNP-2 (WDT:[653..658] which))
            (S
              (NP-SBJ-2 (-NONE-:[658..658] *T*))
              (VP (VBZ:[659..661] is)
                (PP-PRD
                  (ADVP (RB:[662..669] largely))
                  (IN:[670..677] without)
                  (NP
                    (NP
                      (NML (JJ:[678..685] central) (JJ:[686..696] depressant))
                      (NML-1 (-NONE-:[696..696] *P*)))
                    (CC:[697..699] or)
                    (NP (JJ:[700..716] antidopaminergic)
                      (NML-1 (NN:[717..721] side) (HYPH:[721..722] -)
                             (NNS:[722..729] effects)))))))))))
    (.:[729..730] .)))

;sentence 6 Span:732..934
;The aims of this study were to investigate the metabolism of cisapride in
;human  liver microsomes and to determine which cytochrome P-450 (CYP)
;isoenzyme(s) are  involved in cisapride biotransformation.
;[793..802]:substance:"cisapride"
;[853..888]:cyp450:"cytochrome P-450 (CYP) isoenzyme(s)"
;[906..915]:substance:"cisapride"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[732..735] The) (NNS:[736..740] aims))
      (PP (IN:[741..743] of)
        (NP (DT:[744..748] this) (NN:[749..754] study))))
    (VP (VBD:[755..759] were)
      (S-PRP-PRD
        (S
          (NP-SBJ (-NONE-:[759..759] *))
          (VP (TO:[760..762] to)
            (VP (VB:[763..774] investigate)
              (NP
                (NP (DT:[775..778] the) (NN:[779..789] metabolism))
                (PP (IN:[790..792] of)
                  (NP (NN:[793..802] cisapride))))
              (PP-LOC (IN:[803..805] in)
                (NP (JJ:[806..811] human) (NN:[813..818] liver)
                    (NNS:[819..829] microsomes))))))
        (CC:[830..833] and)
        (S
          (NP-SBJ (-NONE-:[833..833] *))
          (VP (TO:[834..836] to)
            (VP (VB:[837..846] determine)
              (SBAR (WDT:[847..852] which)
                (S
                  (NP-SBJ-1
                    (NML
                      (NML (NN:[853..863] cytochrome) (NN:[864..869] P-450))
                      (NML (-LRB-:[870..871] -LRB-) (NN:[871..874] CYP)
                           (-RRB-:[874..875] -RRB-)))
                    (NNS:[876..888] isoenzyme-LRB-s-RRB-))
                  (VP (VBP:[889..892] are)
                    (VP (JJ:[894..902] involved)
                      (NP-1 (-NONE-:[902..902] *))
                      (PP-CLR (IN:[903..905] in)
                        (NP (NN:[906..915] cisapride)
                            (NN:[916..933] biotransformation))))))))))))
    (.:[933..934] .)))

;sentence 7 Span:935..1028
;Additionally, the effects of various  drugs on the metabolism of cisapride
;were investigated.
;[973..978]:substance:"drugs"
;[1000..1009]:substance:"cisapride"
(SENT
  (S
    (ADVP (RB:[935..947] Additionally))
    (,:[947..948] ,)
    (NP-SBJ-1
      (NP (DT:[949..952] the) (NNS:[953..960] effects))
      (PP (IN:[961..963] of)
        (NP (JJ:[964..971] various) (NNS:[973..978] drugs)))
      (PP (IN:[979..981] on)
        (NP
          (NP (DT:[982..985] the) (NN:[986..996] metabolism))
          (PP (IN:[997..999] of)
            (NP (NN:[1000..1009] cisapride))))))
    (VP (VBD:[1010..1014] were)
      (VP (VBN:[1015..1027] investigated)
        (NP-1 (-NONE-:[1027..1027] *))))
    (.:[1027..1028] .)))

;sentence 8 Span:1029..1183
;The major in vitro  metabolite of cisapride was formed by oxidative
;N-dealkylation at the piperidine  nitrogen, leading to the production of
;norcisapride.
;[1049..1059]:substance:"metabolite"
;[1063..1072]:substance:"cisapride"
;[1170..1182]:substance:"norcisapride"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1029..1032] The) (JJ:[1033..1038] major)
        (ADJP (FW:[1039..1041] in) (FW:[1042..1047] vitro))
        (NN:[1049..1059] metabolite))
      (PP (IN:[1060..1062] of)
        (NP (NN:[1063..1072] cisapride))))
    (VP (VBD:[1073..1076] was)
      (VP (VBN:[1077..1083] formed)
        (NP-1 (-NONE-:[1083..1083] *))
        (PP-MNR (IN:[1084..1086] by)
          (NP
            (NP (JJ:[1087..1096] oxidative) (NN:[1097..1098] N)
                (HYPH:[1098..1099] -) (NN:[1099..1111] dealkylation))
            (PP-LOC (IN:[1112..1114] at)
              (NP (DT:[1115..1118] the) (NN:[1119..1129] piperidine)
                  (NN:[1131..1139] nitrogen)))))
        (,:[1139..1140] ,)
        (S-ADV
          (NP-SBJ (-NONE-:[1140..1140] *))
          (VP (VBG:[1141..1148] leading)
            (PP-CLR (TO:[1149..1151] to)
              (NP
                (NP (DT:[1152..1155] the) (NN:[1156..1166] production))
                (PP (IN:[1167..1169] of)
                  (NP (NN:[1170..1182] norcisapride)))))))))
    (.:[1182..1183] .)))

;sentence 9 Span:1184..1340
;By using competitive  inhibition data, correlation studies and heterologous
;expression systems, it was  demonstrated that CYP3A4 was the major CYP
;involved.
;[1306..1312]:cyp450:"CYP3A4"
;[1327..1330]:cyp450:"CYP"
(SENT
  (S
    (PP-MNR (IN:[1184..1186] By)
      (S-NOM
        (NP-SBJ (-NONE-:[1186..1186] *))
        (VP (VBG:[1187..1192] using)
          (NP
            (NP (JJ:[1193..1204] competitive) (NN:[1206..1216] inhibition)
                (NNS:[1217..1221] data))
            (,:[1221..1222] ,)
            (NP (NN:[1223..1234] correlation) (NNS:[1235..1242] studies))
            (CC:[1243..1246] and)
            (NP (JJ:[1247..1259] heterologous) (NN:[1260..1270] expression)
                (NNS:[1271..1278] systems))))))
    (,:[1278..1279] ,)
    (NP-SBJ-1
      (NP (PRP:[1280..1282] it))
      (SBAR-2 (-NONE-:[1282..1282] *EXP*)))
    (VP (VBD:[1283..1286] was)
      (VP (VBN:[1288..1300] demonstrated)
        (NP-1 (-NONE-:[1300..1300] *))
        (SBAR-2 (IN:[1301..1305] that)
          (S
            (NP-SBJ (NN:[1306..1312] CYP3A4))
            (VP (VBD:[1313..1316] was)
              (NP-PRD
                (NP (DT:[1317..1320] the) (JJ:[1321..1326] major)
                    (NN:[1327..1330] CYP))
                (VP (VBN:[1331..1339] involved)
                  (NP (-NONE-:[1339..1339] *)))))))))
    (.:[1339..1340] .)))

;sentence 10 Span:1341..1429
;CYP2A6 also contributed to  the metabolism of cisapride, albeit to a much
;lesser extent.
;[1341..1347]:cyp450:"CYP2A6"
;[1387..1396]:substance:"cisapride"
(SENT
  (S
    (NP-SBJ (NN:[1341..1347] CYP2A6))
    (ADVP (RB:[1348..1352] also))
    (VP (VBD:[1353..1364] contributed)
      (PP-CLR (TO:[1365..1367] to)
        (NP
          (NP (DT:[1369..1372] the) (NN:[1373..1383] metabolism))
          (PP (IN:[1384..1386] of)
            (NP (NN:[1387..1396] cisapride)))))
      (,:[1396..1397] ,)
      (ADVP (IN:[1398..1404] albeit))
      (PP (TO:[1405..1407] to)
        (NP (DT:[1408..1409] a)
          (ADJP (RB:[1410..1414] much) (JJR:[1415..1421] lesser))
          (NN:[1422..1428] extent))))
    (.:[1428..1429] .)))

;sentence 11 Span:1430..1501
;The mean apparent  K(m) against cisapride was 8.6+/-3.5 microM (n = 3).
;[1449..1453]:quantitative-name:"K(m)"
;[1462..1471]:substance:"cisapride"
;[1476..1485]:quantitative-value:"8.6+/-3.5"
;[1486..1492]:quantitative-units:"microM"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1430..1433] The) (JJ:[1434..1438] mean)
          (JJ:[1439..1447] apparent) (NN:[1449..1453] K-LRB-m-RRB-))
      (PP (IN:[1454..1461] against)
        (NP (NN:[1462..1471] cisapride))))
    (VP (VBD:[1472..1475] was)
      (NP-PRD
        (QP (CD:[1476..1479] 8.6) (SYM:[1479..1482] +/-) (CD:[1482..1485] 3.5))
        (NN:[1486..1492] microM)
        (PRN (-LRB-:[1493..1494] -LRB-)
          (S
            (NP-SBJ (NN:[1494..1495] n))
            (VP (SYM:[1496..1497] =)
              (NP (CD:[1498..1499] 3))))
          (-RRB-:[1499..1500] -RRB-))))
    (.:[1500..1501] .)))

;sentence 12 Span:1502..1697
;The peak plasma levels of  cisapride under normal clinical practice are
;approximately 0.17 microM;  therefore it is unlikely that cisapride would
;inhibit the metabolism of  co-administered drugs.
;[1529..1538]:substance:"cisapride"
;[1574..1592]:quantitative-value:"approximately 0.17"
;[1593..1599]:quantitative-units:"microM"
;[1632..1641]:substance:"cisapride"
;[1691..1696]:substance:"drugs"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (DT:[1502..1505] The) (NN:[1506..1510] peak)
            (NN:[1511..1517] plasma) (NNS:[1518..1524] levels))
        (PP (IN:[1525..1527] of)
          (NP (NN:[1529..1538] cisapride)))
        (PP (IN:[1539..1544] under)
          (NP (JJ:[1545..1551] normal) (JJ:[1552..1560] clinical)
              (NN:[1561..1569] practice))))
      (VP (VBP:[1570..1573] are)
        (NP-PRD
          (QP (RB:[1574..1587] approximately) (CD:[1588..1592] 0.17))
          (NN:[1593..1599] microM))))
    (::[1599..1600] ;)
    (S
      (ADVP (RB:[1602..1611] therefore))
      (NP-SBJ
        (NP (PRP:[1612..1614] it))
        (SBAR-1 (-NONE-:[1614..1614] *EXP*)))
      (VP (VBZ:[1615..1617] is)
        (ADJP-PRD (JJ:[1618..1626] unlikely))
        (SBAR-1 (IN:[1627..1631] that)
          (S
            (NP-SBJ (NN:[1632..1641] cisapride))
            (VP (MD:[1642..1647] would)
              (VP (VB:[1648..1655] inhibit)
                (NP
                  (NP (DT:[1656..1659] the) (NN:[1660..1670] metabolism))
                  (PP (IN:[1671..1673] of)
                    (NP
                      (ADJP (AFX:[1675..1677] co) (HYPH:[1677..1678] -)
                            (VBN:[1678..1690] administered))
                      (NNS:[1691..1696] drugs))))))))))
    (.:[1696..1697] .)))

;sentence 13 Span:1698..1815
;In this in vitro study the inhibitory effects of 44 drugs  were tested for
;any effect on cisapride biotransformation.
;[1750..1755]:substance:"drugs"
;[1787..1796]:substance:"cisapride"
(SENT
  (S
    (PP-LOC (IN:[1698..1700] In)
      (NP (DT:[1701..1705] this)
        (ADJP (FW:[1706..1708] in) (FW:[1709..1714] vitro))
        (NN:[1715..1720] study)))
    (NP-SBJ-1
      (NP (DT:[1721..1724] the) (JJ:[1725..1735] inhibitory)
          (NNS:[1736..1743] effects))
      (PP (IN:[1744..1746] of)
        (NP (CD:[1747..1749] 44) (NNS:[1750..1755] drugs))))
    (VP (VBD:[1757..1761] were)
      (VP (VBN:[1762..1768] tested)
        (NP-1 (-NONE-:[1768..1768] *))
        (PP (IN:[1769..1772] for)
          (NP
            (NP (DT:[1773..1776] any) (NN:[1777..1783] effect))
            (PP (IN:[1784..1786] on)
              (NP (NN:[1787..1796] cisapride)
                  (NN:[1797..1814] biotransformation)))))))
    (.:[1814..1815] .)))

;sentence 14 Span:1816..2186
;In conclusion, 34 of  the drugs are unlikely to have a clinically relevant
;interaction; however, the  antidepressant nefazodone, the macrolide
;antibiotic troleandomycin, the HIV-1  protease inhibitors ritonavir and
;indinavir and the calcium channel blocker  mibefradil inhibited the
;metabolism of cisapride and these interactions are  likely to be of clinical
;relevance.
;[1842..1847]:substance:"drugs"
;[1918..1932]:substance:"antidepressant"
;[1933..1943]:substance:"nefazodone"
;[1949..1969]:substance:"macrolide antibiotic"
;[1970..1984]:substance:"troleandomycin"
;[1990..2005]:substance:"HIV-1  protease"
;[2006..2016]:substance:"inhibitors"
;[2017..2026]:substance:"ritonavir"
;[2031..2040]:substance:"indinavir"
;[2049..2056]:substance:"calcium"
;[2065..2072]:substance:"blocker"
;[2074..2084]:substance:"mibefradil"
;[2113..2122]:substance:"cisapride"
(SENT
  (S
    (S
      (PP (IN:[1816..1818] In)
        (NP (NN:[1819..1829] conclusion)))
      (,:[1829..1830] ,)
      (NP-SBJ-2
        (NP (CD:[1831..1833] 34))
        (PP (IN:[1834..1836] of)
          (NP (DT:[1838..1841] the) (NNS:[1842..1847] drugs))))
      (VP (VBP:[1848..1851] are)
        (ADJP-PRD (JJ:[1852..1860] unlikely)
          (S
            (NP-SBJ-2 (-NONE-:[1860..1860] *))
            (VP (TO:[1861..1863] to)
              (VP (VB:[1864..1868] have)
                (NP (DT:[1869..1870] a)
                  (ADJP (RB:[1871..1881] clinically) (JJ:[1882..1890] relevant))
                  (NN:[1891..1902] interaction))))))))
    (::[1902..1903] ;)
    (S
      (S
        (ADVP (RB:[1904..1911] however))
        (,:[1911..1912] ,)
        (NP-SBJ
          (NP
            (NP (DT:[1913..1916] the) (NN:[1918..1932] antidepressant))
            (NP (NN:[1933..1943] nefazodone)))
          (,:[1943..1944] ,)
          (NP
            (NP (DT:[1945..1948] the)
               (NN:[1949..1958] macrolide) (NN:[1959..1969] antibiotic))
            (NP (NN:[1970..1984] troleandomycin)))
          (,:[1984..1985] ,)
          (NP (DT:[1986..1989] the)
            (NML
              (NML
                 (NN:[1990..1995] HIV-1) (NN:[1997..2005] protease)
                (NNS:[2006..2016] inhibitors))
              (NML (NN:[2017..2026] ritonavir) (CC:[2027..2030] and)
                   (NN:[2031..2040] indinavir))))
          (CC:[2041..2044] and)
          (NP
            (NP (VB:[2045..2048] the)
              (NML (NN:[2049..2056] calcium) (NN:[2057..2064] channel))
              (NN:[2065..2072] blocker))
            (NP (NN:[2074..2084] mibefradil))))
        (VP (VBD:[2085..2094] inhibited)
          (NP
            (NP (DT:[2095..2098] the) (NN:[2099..2109] metabolism))
            (PP (IN:[2110..2112] of)
              (NP (NN:[2113..2122] cisapride))))))
      (CC:[2123..2126] and)
      (S
        (NP-SBJ-1 (DT:[2127..2132] these) (NNS:[2133..2145] interactions))
        (VP (VBP:[2146..2149] are)
          (ADJP-PRD (JJ:[2151..2157] likely)
            (S
              (NP-SBJ-1 (-NONE-:[2157..2157] *))
              (VP (TO:[2158..2160] to)
                (VP (VB:[2161..2163] be)
                  (PP-PRD (IN:[2164..2166] of)
                    (NP (JJ:[2167..2175] clinical) (NNS:[2176..2185] relevance))))))))))
    (.:[2185..2186] .)))

;sentence 15 Span:2187..2375
;Furthermore, the antimycotics ketoconazole,  miconazole,
;hydroxy-itraconazole, itraconazole and fluconazole, when  administered orally
;or intravenously, would inhibit cisapride metabolism.
;[2204..2216]:substance:"antimycotics"
;[2217..2229]:substance:"ketoconazole"
;[2232..2242]:substance:"miconazole"
;[2244..2264]:substance:"hydroxy-itraconazole"
;[2266..2278]:substance:"itraconazole"
;[2283..2294]:substance:"fluconazole"
;[2354..2363]:substance:"cisapride"
(SENT
  (S
    (ADVP (RB:[2187..2198] Furthermore))
    (,:[2198..2199] ,)
    (NP-SBJ
      (NP (DT:[2200..2203] the) (NNS:[2204..2216] antimycotics))
      (NP (NN:[2217..2229] ketoconazole) (,:[2229..2230] ,)
          (NN:[2232..2242] miconazole) (,:[2242..2243] ,)
          (NN:[2244..2264] hydroxy-itraconazole) (,:[2264..2265] ,)
          (NN:[2266..2278] itraconazole) (CC:[2279..2282] and)
          (NN:[2283..2294] fluconazole)))
    (,:[2294..2295] ,)
    (SBAR-ADV
      (WHADVP (WRB:[2296..2300] when))
      (S
        (NP-SBJ-1 (-NONE-:[2300..2300] *))
        (VP (VBN:[2302..2314] administered)
          (NP-1 (-NONE-:[2314..2314] *))
          (ADVP-MNR (RB:[2315..2321] orally) (CC:[2322..2324] or)
                    (RB:[2325..2338] intravenously)))))
    (,:[2338..2339] ,)
    (VP (MD:[2340..2345] would)
      (VP (VB:[2346..2353] inhibit)
        (NP (NN:[2354..2363] cisapride) (NN:[2364..2374] metabolism))))
    (.:[2374..2375] .)))

;section 16 Span:2379..2424
;PMID: 10780971 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2379..2383] PMID) (::[2383..2384] :) (CD:[2385..2393] 10780971)
        (NN:[2394..2395] -LSB-) (NNP:[2395..2401] PubMed) (::[2402..2403] -)
        (NN:[2404..2411] indexed) (IN:[2412..2415] for)
        (NNP:[2416..2424] MEDLINE-RSB-)))
